HOLX - Hologic, Inc.
| Previous Close | 54.22 |
| Open | 54.33 |
| Bid | 52.43 x 3100 |
| Ask | 54.99 x 800 |
| Day's Range | 54.21 - 54.73 |
| 52 Week Range | 40.81 - 54.73 |
| Volume | 1,435,110 |
| Avg. Volume | 2,268,447 |
| Market Cap | 14.566B |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | Jan 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.70 |
- Zacks
6 Sector ETFs & Stocks to Watch on December U.S. Inflation
These sector ETFs and stocks should benefit from decent price gains in the month of December.
- GuruFocus.com
Jerome Dodson Exits Signature Bank, Trims Alphabet
Investor's largest sales of the 4th quarter Continue reading...
- Zacks
Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan
Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.
- Business Wire
Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2020
Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2020
- Zacks
DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Insider Monkey
Hologic, Inc. (HOLX) vs. Hedge Fund Favorites in 2019
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
- Business Wire
Hologic to Announce Financial Results for the First Quarter of Fiscal 2020 on Wednesday, January 29, 2020
Hologic to Announce Financial Results for the First Quarter of Fiscal 2020 on Wednesday, January 29, 2020
- Zacks
Hologic (HOLX) Divests Cynosure to Focus on Women's Health
Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.
- Simply Wall St.
Our Take On Hologic, Inc.'s (NASDAQ:HOLX) CEO Salary
In 2013 Steve MacMillan was appointed CEO of Hologic, Inc. (NASDAQ:HOLX). First, this article will compare CEO...
- Business Wire
Hologic to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13 at 8 a.m. Pacific Time.
- Business Wire
Hologic Completes Divestiture of Cynosure Medical Aesthetics Business
Hologic Completes Divestiture of Cynosure Medical Aesthetics Business
- Zacks
Hologic (HOLX) Up 13.2% Since Last Earnings Report: Can It Continue?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Insider Monkey
Hedge Funds Love Hologic, Inc. (HOLX) Way More Than These 3 Stocks
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Investor's Business Daily
Stock Upgrades: Hologic Shows Rising Relative Strength
A Relative Strength Rating upgrade for Hologic shows improving technical performance. Will it continue?
- Zacks
Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA
Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.
- Business Wire
Women’s Healthcare Leader Hologic to Showcase Comprehensive Portfolio of Breast and Skeletal Health Solutions at RSNA 2019
Hologic, Inc. (HOLX) will showcase its comprehensive portfolio of breast and skeletal health products, including screening, interventional, surgical, ultrasound and skeletal solutions, in Booth #2511 at the 105th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago from Dec. 1 to 5. The world leader in mammography, Hologic continues to expand and strengthen its preeminent position in breast health, most recently ranking first in customer satisfaction, service and system performance on the 2019 IMV ServiceTrack™ Diagnostic Imaging report, an annual customer satisfaction survey on the medical imaging industry. Among mammography categories overall, Hologic tops the list for the fourth consecutive year, a testament to the Company’s ongoing dedication to insight-driven innovation, diagnostic leadership, product quality and service in women’s healthcare.
- Zacks
Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark
Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.
- Business Wire
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. announced today that the Company will present at these upcoming investor conferences:
- TEST Business Wire Releases
Newly Published Research Shows that Hologic’s Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods
Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology. The prospective, multi-center clinical study is the first in the United States to formally validate the performance of the Aptima® BV and Aptima® CV/TV assays, available from Hologic, Inc. (Nasdaq: HOLX) on its fully automated Panther® system.
- Zacks
Hologic (HOLX) Set to Divest Medical Aesthetics Business
Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.
- MarketWatch
UPDATE: Hologic to sell underperforming Cynosure business for proceeds of about $138 million
Hologic Inc. said Wednesday it has agreed to sell its Cynosure medical aesthetics business to funds managed by private-equity firm Clayton, Dubilier & Rice for $205 million in cash. The company, which focuses on health care for women, expects to receive net proceeds following closing adjustments of about $138 million. Hologic Chief executive Steve MacMillan said Cynosure, which was acquired in 2017, has "significantly underperformed" expectations. The company will transfer about 825 employees with the change in ownership. The deal is expected to close around year-end. The company expects to book a "significant" non-cash impairment charge in the fourth quarter and an additional $155 million to $185 million pre-tax impairment charge to reduce the carrying value of the asset group to its fair value. "In the first quarter of fiscal 2020, this asset group will meet the criteria for assets held-for sale and will be recorded at fair value less costs to sell, which could result in additional charges," it said in a statement. Hologic is also planning an accelerated share buyback of $205 million. The buyback and sale are expected to raise EPS by about 2 cents in fiscal 2020, while the loss will create a tax refund of at least $300 million that will be received in 2022. Shares rose 1.8% in premarket trade and have gained 14.7% in 2019, while the S&P 500 has gained 24.5%.
- Business Wire
Hologic to Sell Cynosure Medical Aesthetics Business to Clayton, Dubilier & Rice
Hologic, Inc. (HOLX) announced today that it has entered into a definitive agreement to sell its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. Net of these adjustments, Hologic expects net cash proceeds of approximately $138 million. "Divesting our medical aesthetics business will enable us to focus on what we do best – helping women and their families live healthier lives through early detection of disease," said Steve MacMillan, the Company's Chairman, President and Chief Executive Officer.
- PR Newswire
Clayton, Dubilier & Rice to Acquire Market-Leading Medical Aesthetics Technology Company
Carveout Transaction Positions Cynosure for Accelerated Growth Under New Ownership NEW YORK , Nov. 20, 2019 /PRNewswire/ -- Clayton, Dubilier & Rice today announced an agreement under which CD&R-managed ...
